Matinas BioPharma Holdings Business Summary

Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and potential future milestone payments rather than direct product sales. The company’s business model is centered on its proprietary Lipid Nanocrystal (LNC) platform technology, a novel delivery system designed to enable the oral administration of traditionally injectable-only medicines, including small molecules, nucleic acids, and gene therapies. Its primary business segments are focused on the clinical development of its lead internal candidate, MAT2203 (an oral formulation of amphotericin B), and the expansion of its LNC platform through partnerships with global pharmaceutical entities. Matinas competes with drug delivery and biotech firms such as Alector, Beam Therapeutics, Arcturus Therapeutics, and Arcus Biosciences, positioning itself as a niche infrastructure provider in the high-growth oral-delivery and intracellular-targeting market for complex therapeutics. The company is led by Co-founder Jerome D. Jabbour, who serves as Chairman, President, and Chief Executive Officer, and was recently appointed as interim Chief Financial Officer in January 2026. Jabbour brings extensive industry pedigree from his previous roles as Executive Vice President and General Counsel at MediMedia USA and senior leadership positions at Wockhardt Limited and Reliant Pharmaceuticals. The leadership team is supported by a board of directors featuring biotech veterans such as Keith Murphy, the founder of Organovo with a deep background at Amgen, and Edward Neugeboren, a former Chief Strategy Officer at Rising Pharma Holdings. Notable institutional support for the company includes positions held by major investment firms such as Vanguard Group, BlackRock, and Highbridge Capital Management, reflecting continued interest in the scalability of its LNC delivery platform.